These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 29074013)

  • 1. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
    McReelis KD; Lovshin JA
    Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
    [No Abstract]   [Full Text] [Related]  

  • 2. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results from Cardiovascular Outcome Trials in Diabetes.
    Muñoz Torres M; Muñoz Garach A
    Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
    Forst T; Plum-Mörschel L; Weber MM
    Internist (Berl); 2017 Mar; 58(3):293-302. PubMed ID: 28120022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
    Mudher Mikhael E
    J Diabetes Res; 2016; 2016():6962574. PubMed ID: 27642611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 9. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
    Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
    Kuhn A; Park J; Ghazi A; Aroda VR
    Curr Cardiol Rep; 2017 Mar; 19(3):25. PubMed ID: 28251513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon and heart in type 2 diabetes: new perspectives.
    Ceriello A; Genovese S; Mannucci E; Gronda E
    Cardiovasc Diabetol; 2016 Aug; 15(1):123. PubMed ID: 27568179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
    Goncalves E; Bell DSH
    Diabetes Obes Metab; 2017 Jun; 19(6):909-911. PubMed ID: 28176440
    [No Abstract]   [Full Text] [Related]  

  • 18. Updates on cardiovascular outcome trials in diabetes.
    Schnell O; Rydén L; Standl E; Ceriello A;
    Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease.
    Sonoda K; Saguil A
    Am Fam Physician; 2022 Jul; 106(1):24-25. PubMed ID: 35839371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.